Ligandal

Ligandal's mission is to create precision delivery platform to cure and treat disease. We are driving the discovery and delivery of a broad array of gene therapies, genetic materials, and gene-specific payloads with unprecedented precision at the cellular and sub-cellular level. Our ligand discovery engine allows for rapid design of diagnostically-responsive materials, capable of shuttling a variety of nucleic acid and protein payloads (including CRISPR and mRNA) to specific cell types. We are initially applying this technology to indications in hematology, immuno-oncology, and infectious disease.

Ligandal headquartered in New York, United States, North America, operates in the Biotechnology, Genetics, Nanotechnology sector. The company focuses on Biotechnology and has secured $390.1M in funding across 84 round(s). With a team of 1-10 employees, Ligandal is actively contributing to advancements in Biotechnology. Their latest funding round, Convertible Note - Ligandal, raised $64.0K. Discover more about their projects, partnerships, and impact on our platform.